Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 1, 2011, Pages 122-130

  Robich, Michael P ^a,b,c   Chu, Louis M ^a   Burgess, Thomas A ^c   Feng, Jun ^c   Bianchi, Cesario ^c   Sellke, Frank W ^a,c  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

cyclooxygenase inhibition; microvascular reactivity; Myocardial physiology; prostaglandins

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN; SEROTONIN; THROMBOXANE; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTERY CONSTRICTION; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENZYME INHIBITION; HEART FUNCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HEART SARCOMA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PH MEASUREMENT; PHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; SWINE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; EPOPROSTENOL; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; PERFUSION; RISK; SWINE; SWINE, MINIATURE; THROMBOXANES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78951474168     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182010a96     Document Type: Article

References (29)

1. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284: 1247-1255.
2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343: 1520-1528, 1522.
3. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103:1227-1237.
4. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006; 119:255-266.
5. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol. 2006;98:266-274.
6. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
7. Dogne JM, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem. 2005;48:2251-2257.
8. Solomon SD,Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117:2104-2113.
9. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642.
10. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665-674.
11. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96: 272-277.
12. Osipov RM, Robich MP, Feng J, et al. Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection. J Cardiovasc Pharmacol. 2009;54:287-297.
13. Boodhwani M, Voisine P, Ruel M, et al. Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction. Eur J Cardiothorac Surg. 2008;33:645-650; discussion 251-642.
14. Robich MP, Araujo EG, Feng J, et al. Altered coronary microvascular serotonin receptor expression after coronary artery bypass grafting with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 139:1033-1040.
15. Li H, Hortmann M, Daiber A, et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther. 2008;326:745-753.
16. Tsoyi K, Kim HJ, Shin JS, et al. HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008; 20:1839-1847.
17. Johnson AG, Nguyen TV, Owe-Young R, et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens. 1996;10:257-261.
18. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619-1632.
19. Hoenig MR, Bianchi C, Rosenzweig A, et al. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol. 2008;6:292-300.
20. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999; 12(2 pt 2):S50-S55.
21. Wu G, Mannam AP, Wu J, et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol. 2003;285:H2420-H2429.
22. Meier P, Gloekler S, Zbinden R, et al. Beneficial effect of recruitable collaterals: a 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation. 2007;116:975-983.
23. Robich MP, Chu LM, Feng J, et al. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium. J Thorac Cardiovasc Surg. 2010;140:1143-1152.
24. Feigl EO. Coronary autoregulation. J Hypertens Suppl. 1989;7:S55-S58; discussion S59.
25. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev. 2008;88:1009-1086.
26. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res. 2009;81: 449-456.
27. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alphainduced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-2865.
28. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene. 2003;22:8983-8998.
29. Dhingra S, Sharma AK, Singla DK, et al. p38 and ERK1/2 MAPKs mediate the interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. 2007;293:H3524-H3531.